Table 2 Analysis of putative prognostic factors in CAEBV patients
From: Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein–Barr virus infection
Variables | Univariate analysis | |
|---|---|---|
Hazard ratio (95% CI) | P value | |
Age (≥ 4.5 years) | 4.72 (0.82–10.68) | 0.097 |
Time of EBV infection to diagnosis (≥ 12 months) | 1.56 (0.39–7.80) | 0.485 |
Liver (≥ 3.9 cm) | 0.76 (0.18–3.19) | 0.726 |
Spleen (≥ 4.1 cm) | 1.38 (0.38–5.19) | 0.602 |
AST (≥ 150 U/l) | 0.64 (0.17–2.59) | 0.570 |
ALT (≥ 100 U/l) | 0.64 (0.17–2.60) | 0.567 |
Fib (< 1.5 g/l) | 0.51 (0.11–2.88) | 0.511 |
Complicated with HLH | 1.10 (0.32–3.70) | 0.878 |
EBV-DNA in blood (≥ 5.0 × 106 copies/ml) | 0.93 (0.25–3.44) | 0.918 |
EBV-DNA in plasma (≥ 1.0 × 105 copies/ml) | 1.15 (0.23–5.83) | 0.850 |
Chemotherapy (≥ 3 course) | 0.31 (0.04–2.07) | 0.235 |
Clinical CR | 0.68 (0.19–2.27) | 0.520 |
Clinical PR | 1.19 (0.24–6.16) | 0.818 |
Virological CR | 1.48 (0.28–9.26) | 0.607 |
Virological PR | 1.96 (0.57–6.28) | 0.301 |
EBV-T cell | 0.53 (0.10–1.68) | 0.249 |
EBV-NK cell | 0.56 (0.09–3.52) | 0.543 |
EBV-T/NK cell | 0.38 (0.05–2.95) | 0.355 |